| Date | Title | Description |
| 21.08.2026 | Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ) | Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ)
Fri, Aug 21, 2026 07:30 CET Report this content
Lund, Sweden August 21, 2026, Hansa Biopharma AB (publ), Reg. No. 556734-5359 (“Hansa Biopharma”), with registered office i... |
| 19.04.2022 | Bear market shows no signs of abating, claiming Finch Therapeutics as the latest layoff victim | Much ink has been spilled over the continuing wave of layoffs hitting the biotech industry, and that doesn’t look to be stopping anytime soon.
Finch Therapeutics reported Tuesday morning that it would be laying off 37 staff... |
| 20.10.2021 | Finch Therapeutics : Jefferies Virtual Next Generation IBD Therapeutics Summit Presentation | Harnessing the Genomic Revolution & Machine Learning to Pioneer Microbiome Therapeutics
Jefferies Virtual Next Generation IBD Therapeutics Summit October 2021
Forward-Looking Statements
Statements contained in this presentation regardin... |
| 03.06.2021 | Gut therapy: MicrobiomX raises $1M for stool collection and processing device, analysis service | MicrobiomX’s device for stool collection also extrudes stool into capsules. (MicrobiomX Photo)
New funding: MicrobiomX, a Seattle startup developing a device to collect and process stool samples for clinical use, has raised $1 million in a ... |
| 21.09.2020 | Microbiome Drug Development Company Finch Therapeutics Raises $90 Million | Clinical-stage microbiome drug development company Finch Therapeutics announced that it has raised a $90 million Series D funding round
Clinical-stage microbiome drug development company Finch Therapeutics announced that it has raised a $90... |
| 17.09.2020 | Finch Therapeutics Announces $90M Financing |
SOMERVILLE, MA, Finch Therapeutics Group, a clinical-stage microbiome drug development company, announced today a $90 million Series D financing.
>> Click here for more funding data on Finch Therapeutics Group
>> To export F... |
| 17.09.2020 | Finch Therapeutics Raises $90M in Series D Financing | Finch Therapeutics Group, Inc., a Somerville, Mass.-based clinical-stage microbiome drug development company, raised $90m in Series D financing.
Backers included new investors Baupost Group, Humboldt Fund, MSD Capital, MSD Partners, Octave ... |
| 17.09.2020 | Finch Therapeutics Announces $90 Million Financing | SOMERVILLE, Mass.--(BUSINESS WIRE)--Finch Therapeutics Group, Inc., a clinical-stage microbiome drug development company, announced today a $90 million Series D financing. New investors in the round include Baupost Group, Humboldt Fund, MSD... |
| 17.09.2020 | Finch nets $90M to push C. diff microbiome med toward FDA filing, move into hep B, autism | According to the Centers for Disease Control and Prevention, 47 million courses (PDF) of antibiotics were prescribed for infections that didn’t need them in 2018. And taking antibiotics is “like carpet bombing your microbiome," Finch T... |
| 17.09.2020 | OCV Partners Participates in Finch Therapeutics’ Oversubscribed $90 Million Financing to Advance its Pipeline of Investigational Oral Microbiome Drugs | Somerville, MA, September 17, 2020 – Finch Therapeutics Group, Inc. (“Finch”), a clinical-stage microbiome drug development company, announced today an oversubscribed $90 million Series D financing. |
| 08.01.2020 | Finch Therapeutics Completes Enrollment in Potentially Pivotal Trial of CP101, an Investigational Oral Full-Spectrum Microbiota® Therapy for the Prevention of Recurrent C. difficile Infection | Somerville, MA (January 8, 2020) — Finch Therapeutics Group, Inc. (“Finch”), a clinical-stage microbiome therapeutics company, announced today that it has completed enrollment in PRISM3, its multi-center, placebo-controlled Phase 2 clinical... |
| 25.08.2019 | Finch Therapeutics Raises $53M Series C | SOMERVILLE, Mass.--(BUSINESS WIRE)--Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today the completion of a $53 million Series C financing. The financing comes from new investors including OCV P... |
| 23.08.2019 | Finch Therapeutics Group Receives $53M |
SOMERVILLE, MA. Finch Therapeutics Group, a clinical-stage microbiome therapeutics company, announced today the completion of a $53 million Series C financing.
>> Click here for more funding data on Finch Therapeutics Group
>&g... |
| 22.08.2019 | Finch Therapeutics Raises $53M in Series C Funding | Finch Therapeutics Group, Inc., a Somerville, MA-based clinical-stage microbiome therapeutics company, completed a $53m Series C financing.
Backers included OCV Partners, Susquehanna International Group (SIG), Symbiosis LLC and the Trans-Pa... |
| 22.08.2019 | Finch Therapeutics Raises $53M In Series C | SOMERVILLE, Mass.--(BUSINESS WIRE)--Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today the completion of a $53 million Series C financing. The financing comes from new investors including OCV P... |
| 22.08.2019 | Finch Therapeutics Raises $53 Million to Advance Microbiome-Based Therapies for Recurrent C. Difficile, Autism and other Disease Areas | Somerville, MA (August 22, 2019) — Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today the completion of a $53 million Series C financing. The financing comes from new investors including OCV Pa... |
| 17.04.2019 | As researchers pursue links between bacteria and human health, startups stand to benefit | In 2009, the National Institutes of Health launched a five-year, $150 million project to stimulate research into a new field of medicine examining the connections between the millions of bacteria living in the human gut and overall human he... |
| 19.06.2018 | 15 Boston Microbiome Startups to Watch | “Bacteria, it’s the only culture some people have!”
If you spot someone wearing a tee shirt with that saying, there is some chance they work at a microbiome startup. If they don’t, it’s probably worth looking into.
The human microbiome is a... |
| 05.03.2018 | Finch Therapeutics Group Inks $36M in Series B |
SOMERVILLE, MA, Privately held microbiome therapeutics company, announced today the successful close of an oversubscribed $36 million Series B financing.
>> Click here for more funding data on Finch Therapeutics Group
>> To ... |
| 05.03.2018 | Term Sheet — Monday, March 5 | M&A DRAMA
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
CHANGE OF PLANS: The U.S. Treasury just threw a new twist in Broadcom’s proposed takeover of chipmaker Qualcomm. Regulators have ... |
| 01.03.2018 | Finch Therapeutics Group Raises $36M in Series B Financing | Finch Therapeutics Group, Inc., a Somerville, Mass.-based microbiome therapeutics company, closed a $36m Series B financing.
Investors included Shumway Capital, Willett Advisors, Morgan Noble and Avenir Growth Capital.
The round brings the ... |
| 01.03.2018 | Finch Therapeutics Group Raises $36 Million Series B | SOMERVILLE, Mass.--(BUSINESS WIRE)--Finch Therapeutics Group, Inc. (Finch), a privately held microbiome therapeutics company, announced today the successful close of an oversubscribed $36 million Series B financing, bringing the total capit... |
| 06.04.2017 | The expanding ecosystem of microbiome startups | Somerville, Massachusetts-based Finch Therapeutics announced a new agreement with Takeda Pharmaceuticals on Wednesday, a solid endorsement of its sophisticated bioinformatics platform.
Along with oncology and central nervous system disorder... |
| 05.04.2017 | Finch Therapeutics, Takeda ink new microbiome GI collab | Microbiome biotech Finch Therapeutics has signed a pact with perennial U.S. life sciences dealmaker Takeda to jointly work on FIN-524, a microbial cocktail for inflammatory bowel disease (IBD).
Somerville, Massachusetts-based Finch Therapeu... |
| - | Meet the 30 young leaders forging a new future for the healthcare industry in 2021 | From left: Dr. Isaac Kinde, Thrive's cofounder and head of research and innovation; Dr. Asima Ahmad, a cofounder and the chief medical officer of Carrot Fertility; Harpreet Singh Rai, the CEO of Oura; and Deena Shakir, a partner at Lux Capi... |
| - | The expanding ecosystem of microbiome startups | More funding and another powerful pharma backer have entered the microbiome space, showing that at least some investors and pharma execs believe the field can begin converting preclinical ideas into valid human therapies.
Finch Therapeutics... |
| - | OCV Partners Participates in Finch Therapeutics’ Oversubscribed $90 Million Financing to Advance its Pipeline of Investigational Oral Microbiome Drugs | Proceeds to support the advancement of lead candidate through the final stages of clinical development for recurrent C. difficile infection, and the advancement into the clinic of programs for autism spectrum disorder and chronic hepatitis ... |
| - | Meet the top young leaders transforming the biotech industry | From left: Dr. Isaac Kinde, head of research and innovation and a co-founder of Thrive, Dr. Asima Ahmad, Carrot Fertility cofounder and chief medical officer, Harpreet Singh Rai, Oura CEO, and Deena Shakir, Lux Capital partner. Thrive; Carr... |
| - | Finch Therapeutics Raises $53 Million to Advance Microbiome-Based Therapies for Recurrent C. Difficile, Autism and other Disease Areas | Somerville, MA (August 22, 2019) — Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today the completion of a $53 million Series C financing. The financing comes from new investors including OCV Pa... |
